Please login to the form below

Not currently logged in

AZ agrees cancer alliance with Immunocore

Medimmune subsidiary will work with biotech on encouraging patient's immune system to tackle tumours

AstraZeneca's Medimmune subsidiary announced a collaboration this morning with UK company Immunocore that will focus on the development of cancer therapeutics.

The two companies will work on new drug based on Immunocore's Immune Mobilising Monoclonal T-Cell Receptor against Cancer (ImmTAC) technology, which encourages a patient's own immune system to tackle tumours.

The deal potentially covers a number of targets, with AZ offering an upfront fee of $20m and up to $300m in development and milestone payments per programme, plus royalties if any of the therapies reach the market.

Immunocore also has collaborations in place with GlaxoSmithKline and Roche/Genentech, as well as its own melanoma therapy in phase II testing.

Article by
Phil Taylor

9th January 2014

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

Latest intelligence

Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...
figure 1
The valuable brand
Creating value beyond the pill is both possible and increasingly necessary...
The rise of real-world evidence
Demonstrating efficacy and value requires more than clinical trial data...